Free shipping on all orders over $ 500

Roflumilast

Cat. No. M1871

All AbMole products are for research use only, cannot be used for human consumption.

Roflumilast Structure
Synonym:

APTA-2217; BYK 20869; B9302-107

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
1mg USD 25  USD25 In stock
5mg USD 50  USD50 In stock
10mg USD 65  USD65 In stock
25mg USD 140  USD140 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Roflumilast (APTA-2217; BYK 20869; B9302-107) is a novel and selective, long-acting inhibitor of phosphodiesterase 4 (PDE-4) with IC50 of 0.8 nM. It has antiinflammatory effects for the treatment of inflammatory conditions of the lungs such as asthma, and chronic obstructive pulmonary disease (COPD). Roflumilast is a first-in-class antiinflammatory treatment for severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of frequent exacerbations. Because roflumilast (a phosphodiesterase-4 inhibitor) has a different mode of action to bronchodilators and inhaled corticosteroids, it may provide additional benefits when added to treatments in frequent exacerbators. Roflumilast lowered glucose levels in patients with newly diagnosed DM2 without COPD, suggesting positive effects on glucose homoeostasis.

Chemical Information
Molecular Weight 403.21
Formula C17H14Cl2F2N2O3
CAS Number 162401-32-3
Solubility (25°C) DMSO 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Related PDE Products
MR-L2

MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM.

MMPX

MMPX is a potent PDE1 inhibitor.

T-0156 

T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor.

TPN171 

TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH).

Mesopram

Mesopram (Daxalipram) is an orally active phosphodiesterase (PDE) 4 inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: Roflumilast, APTA-2217; BYK 20869; B9302-107 supplier, PDE, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.